Data demonstrate potent multi-target activity, high specificity, and a novel approach to overcoming fundamental limitations of T cell engagers in solid tumors April 20, 2026 -- Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17–22 in San Diego, California. The data were included

AstraZeneca announced Tuesday that a Phase III study of Ultomiris (ravulizumab) in adults with IgA nephropathy (IgAN) met its primary endpoint, setting up marketing applications for the long-acting C5 complement inhibitor in this indication. "These positive data demonstrate that C5 complement inhibition with Ultomiris results in a rapid and clinically meaningful reduction in proteinuria as early as week 10 and underscores its potential as a disease-modifying approach in IgAN," said Marc Dunoyer

Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion's commitment to elevating the standard of care and addressing unmet medical need in gastroenterology April 21, 2026 -- Celltrion, Inc. today announced that seven abstrac

Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indication in cisplatin-ineligible muscle-invasive bladder cancer (MIBC), if approved, this regimen would be the first and only perioperative treatment for patients with MIBC regardless of cisplatin eligibility, marking a potential new standard of care April 20, 2026 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer

April 20, 2026 -- Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies. Autologous CAR-T therapy has achieved remarkable success in hematologic malignancies, yet its widespread use remains challenging

Novo Nordisk said Monday that its sickle cell disease pill succeeded in a late-stage study. However, the data came in behind expectations the company set last year. Etavopivat cut the occurrence of the painful sickle cell complications known as vaso-occlusive crises (VOCs) by 27% compared with placebo, hitting one of the trial’s co-primary endpoints. However, the company’s then-head of rare disease Ludovic Helfgott told Endpoints News last year that Novo was hoping to see a 50% cut. Nonetheles

New data demonstrate the IL-22 AND-Body™ therapeutic, AMP-220, selectively targets gut tissue, conferring improved therapeutic efficacy and tolerability in vivo IND-enabling studies for AMP-220 are ongoing April 20, 2026 -- Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced new preclinical data for AMP-220, a gut-targeted IL-22 AND-Body™ therapeutic. The data wer

ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer, accounting for 10-15% of all lung cancer diagnoses [3]-[6] Lung cancer is the leading cause of cancer death in Australia and among men in Singapore, and the second highest among Singaporean women [7]-[9] April 20, 20

While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to a new study awaiting peer review. The analysis, shared as a preprint, spotlights the fierce competition between Lilly and Novo in the weight loss drug market. Both companies have been trying to edge the other out by showcasing value-added drug features as well as investing in next-generation approaches and advancing oral formulations.

Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with cabozantinib, with tumor shrinkage observed in 75% of patients Responses observed in heavily pretreated patients, including those with stable disease on prior cabozantinib Durable treatment durations reaching 56 weeks, with one-third of patients remaining on therapy at time of data cut-off